Literature DB >> 11578958

Mucins in the gastrointestinal tract in health and disease.

A P Corfield1, D Carroll, N Myerscough, C S Probert.   

Abstract

Mucins form part of the dynamic, interactive mucosal defensive system active at the mucosal surface of the gastrointestinal tract. They are carbohydrate rich glycoproteins with unique molecular structure and chemical properties. The family of mucin (MUC) genes has 13 members that can be divided into secreted and membrane-associated forms each with characteristic protein domains and tissue specific glycosylation. Biosynthetic pathways have been described for the secreted and membrane-associated mucins and their eventual degradation and turnover. Mucins are present at all mucosal surfaces throughout the body in typical combinations and relate to the demands of organ function. Patterns of MUC gene expression with gastrointestinal site specific glycosylation are clearly important but are not yet well defined. Mucin production during fetal development shows distinct patterns that may correlate in many cases with neoplastic expression in adult life. An increasing number of protective proteins have been identified that appear in the adherent mucus layer at the mucosal surface. These proteins are co-secreted with mucins in some cases, interact with mucins at a molecular level through peptide and carbohydrate sites or benefit from the viscoelastic, aqueous environment afforded by the mucus gel to effect their defensive roles. The mechanism of many of these interaction remains to be elucidated but is clearly part of an integrated innate and adaptive mucosal defensive system relying on the mucins as an integral component to provide a mucus gel. Recent improvements in the description of MUC gene expression and mature mucin synthesis in the healthy gastrointestinal tract has formed a basis for assessment of mucosal disease at sites throughout the tract. Pathological patterns of mucin expression in disease appear to follow tissue phenotype, so that gastric and intestinal types can be defined and appear in metaplasia in e.g. esophagus and stomach. Adaptation of previous mucin based, histochemical classification of intestinal metaplasia to assess MUC gene expression has proved helpful and promises greater value if reliably combined with mucin linked glycosylation markers. Few changes in MUC gene expression or polymorphism have been detected in inflammatory bowel diseases in contrast to malignant transformation. Glycosylation changes however, are evident in both types of disease and appear to be early events in disease pathogenesis. Review of the major mucosal diseases affecting the gastrointestinal tract in childhood reveals parallel patterns to those found in adult pathology, but with some novel conditions arising through the developmental stages at lactation and weaning. The impact of bacterial colonization and nutrition at these stages of life are important in the evaluation of mucosal responses in pediatric disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11578958     DOI: 10.2741/corfield

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  95 in total

Review 1.  Spectrum of mucin-producing neoplastic conditions of the abdomen and pelvis: cross-sectional imaging evaluation.

Authors:  Nam Kyung Lee; Suk Kim; Hyun Sung Kim; Tae Yong Jeon; Gwang Ha Kim; Dong Uk Kim; Do Youn Park; Tae Un Kim; Dae Hwan Kang
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

2.  A signaling mucin at the head of the Cdc42- and MAPK-dependent filamentous growth pathway in yeast.

Authors:  Paul J Cullen; Walid Sabbagh; Ellie Graham; Molly M Irick; Erin K van Olden; Cassandra Neal; Jeffrey Delrow; Lee Bardwell; George F Sprague
Journal:  Genes Dev       Date:  2004-07-15       Impact factor: 11.361

Review 3.  Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.

Authors:  S Bafna; S Kaur; S K Batra
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

Review 4.  The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 5.  Structure, evolution, and biology of the MUC4 mucin.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Surinder K Batra
Journal:  FASEB J       Date:  2007-11-16       Impact factor: 5.191

Review 6.  Intestinal crosstalk: a new paradigm for understanding the gut as the "motor" of critical illness.

Authors:  Jessica A Clark; Craig M Coopersmith
Journal:  Shock       Date:  2007-10       Impact factor: 3.454

7.  Distribution of mucins and antimicrobial substances lysozyme and lactoferrin in the laryngeal subglottic region.

Authors:  Hannes Kutta; Andreas Willer; Philipp Steven; Lars Bräuer; Michael Tsokos; Friedrich Paulsen
Journal:  J Anat       Date:  2008-07-22       Impact factor: 2.610

Review 8.  Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases.

Authors:  Daniel A Peterson; Daniel N Frank; Norman R Pace; Jeffrey I Gordon
Journal:  Cell Host Microbe       Date:  2008-06-12       Impact factor: 21.023

9.  Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13.

Authors:  Robert Bucki; Dorota B Namiot; Zbigniew Namiot; Paul B Savage; Paul A Janmey
Journal:  J Antimicrob Chemother       Date:  2008-05-01       Impact factor: 5.790

Review 10.  Pathogenesis of NEC: Role of the innate and adaptive immune response.

Authors:  Timothy L Denning; Amina M Bhatia; Andrea F Kane; Ravi M Patel; Patricia W Denning
Journal:  Semin Perinatol       Date:  2016-12-09       Impact factor: 3.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.